The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval-Reference-Cited by-同舟云学术

The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval

Published:2021-10-08 Issue:10 Volume:2 Page:e213184
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Darrow Jonathan J.¹²

Affiliation:

1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

2. Department of Law and Taxation, Bentley University, Waltham, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2784985/darrow_2021_ic_210013_1633558723.83888.pdf

Reference10 articles.

1. Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval.;Sachs;JAMA Health Forum,2021

2. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials.;Chen;JAMA Intern Med,2019

3. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases.;Miyamoto;Orphanet J Rare Dis,2011

4. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.;Beaver;JAMA Oncol,2018

5. How do payers respond to regulatory actions? the case of bevacizumab.;Dusetzina;J Oncol Pract,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017;JAMA Health Forum;2022-05-27